Related Experiment Video
Updated: Jul 5, 2025

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic
Pramit Kumar Ghosh1, Amlan Ghosh2,3
1Department of Life Sciences, Presidency University, Kolkata, West Bengal, India.
Abstract:
Chordoma is a rare form of bone cancer develops in the spinal cord and skull. Instead of conventional (radio/chemotherapies) and targeted therapies, the disease is associated with high rate of recurrence and poor patient survival. Thus, for better disease management, the molecular pathogenesis of chordoma should be studied in detail to identify dysregulated biomolecules that can be targeted by novel therapeutics. Recent research showed frequent dysregulation of long noncoding RNA (lncRNA), microRNA (miRNA), and circular RNA (circRNA) in association with aggressive tumor phenotypes like cell proliferation, migration, invasion, and metastasis in a variety of cancers, including chordoma. Apart from diagnostic and prognostic importance, noncoding RNAs may serve as promising targets for novel therapeutics in cancer. In this review, we summarized a list of miRNAs, lncRNAs, and circRNA found to be dysregulated in chordoma from available data published in relevant databases (PubMed), as such an approach seems to be rare to date. The dysregulated noncoding RNAs were also associated with adverse tumor phenotypes to assess the impact on disease pathogenesis and, associated downstream molecular pathways were focused. Synthetic compounds and natural products that were reported to target the noncoding RNAs in other malignancies were also listed from published literature and proposed as potential therapeutic agents in chordoma. This review will provide information for further research on chordoma focusing on detailed characterization of dysregulated lncRNAs, miRNAs, and circRNA to understand the disease pathogenesis and, exploration of suitable natural and synthetic products targeting dysregulated non-coding RNAs to develop effective therapeutic measures.
Insights
Chordoma, a rare bone cancer, shows high recurrence. This review details dysregulated noncoding RNAs (ncRNAs) like lncRNAs, miRNAs, and circRNAs, offering potential therapeutic targets for improved chordoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chordoma is a rare, aggressive bone cancer of the spine and skull.
- Conventional therapies show limited efficacy, leading to high recurrence and poor survival rates.
- Understanding chordoma's molecular pathogenesis is crucial for developing novel therapeutics.
Purpose of the Study:
- To review dysregulated noncoding RNAs (ncRNAs) in chordoma.
- To associate these ncRNAs with tumor progression and molecular pathways.
- To identify potential therapeutic agents targeting ncRNAs in chordoma.
Main Methods:
- Literature review of dysregulated miRNAs, lncRNAs, and circRNAs in chordoma.
- Analysis of associations between ncRNAs, tumor phenotypes, and molecular pathways.
- Compilation of natural and synthetic compounds targeting ncRNAs in other cancers.
Main Results:
- Identified specific dysregulated long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs) in chordoma.
- Demonstrated links between these ncRNAs and aggressive tumor behaviors (proliferation, migration, invasion, metastasis).
- Highlighted downstream molecular pathways influenced by dysregulated ncRNAs.
Conclusions:
- Dysregulated ncRNAs are implicated in chordoma pathogenesis and progression.
- ncRNAs represent promising diagnostic, prognostic, and therapeutic targets for chordoma.
- Natural and synthetic compounds targeting ncRNAs warrant investigation for chordoma treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Abnormal Proliferation
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
MicroRNAs
Regulation of Expression at Multiple Steps
Epigenetic Regulation
X-chromosome...

